Join
Live feed
·
PRReleasevia Quantisnow
Repare Therapeutics Inc. logo

Repare Therapeutics Presents Updated Clinical Data from the Ongoing Phase 1/2 TRESR Study of RP-3500 Monotherapy in Solid Tumors at the 2022 AACR Annual Meeting

ByQuantisnow·Wall Street's wire, on your screen.
RPTX· Repare Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track RPTX (Repare Therapeutics Inc.) and more on Quantisnow.